Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) PT at $6.63

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight ratings firms that are currently covering the stock, MarketBeat reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $6.63.

Several research analysts have commented on the stock. Canaccord Genuity Group boosted their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Friday, November 15th. Chardan Capital reiterated a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Cantor Fitzgerald restated an "overweight" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Needham & Company LLC reissued a "buy" rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research report on Monday, January 6th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Creative Planning acquired a new stake in shares of Taysha Gene Therapies during the third quarter worth about $28,000. Ground Swell Capital LLC purchased a new stake in Taysha Gene Therapies during the 4th quarter valued at approximately $25,000. Cibc World Markets Corp acquired a new stake in Taysha Gene Therapies during the 4th quarter worth approximately $28,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies during the 4th quarter worth approximately $31,000. Finally, Hsbc Holdings PLC grew its stake in shares of Taysha Gene Therapies by 65.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after purchasing an additional 8,076 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company's stock.

Taysha Gene Therapies Stock Up 0.6 %

Shares of TSHA stock traded up $0.01 during trading hours on Friday, reaching $1.63. 1,207,810 shares of the stock were exchanged, compared to its average volume of 2,059,431. The business's fifty day moving average is $1.76 and its two-hundred day moving average is $2.01. The firm has a market capitalization of $334.05 million, a P/E ratio of 2.59 and a beta of 0.92. Taysha Gene Therapies has a 12-month low of $1.19 and a 12-month high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.